|
|
|
Latest News |
| |
Chronic fatigue syndrome patients need an effective therapeutic, leading expert argues
Ampligen, the first drug ever seeking approval to treat chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), recently hit another roadblock with the U.S. Food and Drug Administration (FDA). In its long quest to treat 1 million Americans suffering from this debilitating illness, the FDA advisory panel did not recommend the drug to be sold on the market, largely because CFS/ME doesn't have clear biomarkers such as blood tests to define patients who most likely to respond to the drug. A leading clinician argues that the real loser is not Ampligen, but CFS/ME patients whose daily suffering continues to be unabated.
View full story
|
| |
| |
| |
|
|
| |
|
|
|
|
|
 |
|
Sign up
Receive our
free newsletter.
View past issues |
| |
Very interesting.
I
especially liked the jungle test in the fun tests.
- Dan Bierenga
|
|
|
All fun and informative tests,
I shared them
with all my friends. Great way to better understand folks.
- Matthew McAvoy |
|
|
|
|
|
|
 |
|
